CD133 + liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma

Lian Shu Piao; Wonhee Hur; Taek Kyun Kim; Sung Woo Hong; Sung Woo Kim; Jung Eun Choi; Pil Soo Sung; Myeong Joon Song; Byeong Chel Lee; Daehee Hwang; Seung Kew Yoon

doi:10.1016/j.canlet.2011.10.012

CD133 ⁺ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma

Lian Shu Piao
, Wonhee Hur
, Taek Kyun Kim
, Sung Woo Hong
, Sung Woo Kim
, Jung Eun Choi
, Pil Soo Sung
, Myeong Joon Song
, Byeong Chel Lee
, Daehee Hwang
, Seung Kew Yoon

The Catholic University of Korea
Dalian University
Pohang University of Science and Technology
University of Pittsburgh

Research output: Contribution to journal › Article › peer-review

197 Scopus citations

Abstract

CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure showed higher activation of MAPK/PI3K signaling pathway and reduction in reactive oxygen species levels compared to CD133 ^- cells. The in vivo study with a xenograft model showed increased tumor formation in irradiated CD133 ⁺ cell-injected nude mice compared to the CD133 ^- group, suggesting that CD133 contributes to radioresistance in HCC. Therefore, CD133-expressing liver cancer cells have anti-apoptotic and radioresistance properties that may be useful to improve anti-cancer treatments, including chemotherapy/radiotherapy of HCC.

Original language	English
Pages (from-to)	129-137
Number of pages	9
Journal	Cancer Letters
Volume	315
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2011.10.012
State	Published - 28 Feb 2012

Bibliographical note

Funding Information:
This work was funded by the Nuclear R&D Program of the Ministry of Science and Technology, the Republic of Korea (No. 2010-0017595 ) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0027071 ).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CD133
Cancer stem cell
Hepatocellular carcinoma
Microarray
Radioresistance

Access to Document

10.1016/j.canlet.2011.10.012

Cite this

@article{d0971c01adf94d4ea975746e0d6f1735,

title = "CD133 + liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma",

abstract = "CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure showed higher activation of MAPK/PI3K signaling pathway and reduction in reactive oxygen species levels compared to CD133 - cells. The in vivo study with a xenograft model showed increased tumor formation in irradiated CD133 + cell-injected nude mice compared to the CD133 - group, suggesting that CD133 contributes to radioresistance in HCC. Therefore, CD133-expressing liver cancer cells have anti-apoptotic and radioresistance properties that may be useful to improve anti-cancer treatments, including chemotherapy/radiotherapy of HCC.",

keywords = "CD133, Cancer stem cell, Hepatocellular carcinoma, Microarray, Radioresistance",

author = "Piao, \{Lian Shu\} and Wonhee Hur and Kim, \{Taek Kyun\} and Hong, \{Sung Woo\} and Kim, \{Sung Woo\} and Choi, \{Jung Eun\} and Sung, \{Pil Soo\} and Song, \{Myeong Joon\} and Lee, \{Byeong Chel\} and Daehee Hwang and Yoon, \{Seung Kew\}",

note = "Funding Information: This work was funded by the Nuclear R\&D Program of the Ministry of Science and Technology, the Republic of Korea (No. 2010-0017595 ) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0027071 ). ",

year = "2012",

month = feb,

day = "28",

doi = "10.1016/j.canlet.2011.10.012",

language = "English",

volume = "315",

pages = "129--137",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - CD133 + liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma

AU - Piao, Lian Shu

AU - Hur, Wonhee

AU - Kim, Taek Kyun

AU - Hong, Sung Woo

AU - Kim, Sung Woo

AU - Choi, Jung Eun

AU - Sung, Pil Soo

AU - Song, Myeong Joon

AU - Lee, Byeong Chel

AU - Hwang, Daehee

AU - Yoon, Seung Kew

N1 - Funding Information: This work was funded by the Nuclear R&D Program of the Ministry of Science and Technology, the Republic of Korea (No. 2010-0017595 ) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0027071 ).

PY - 2012/2/28

Y1 - 2012/2/28

N2 - CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure showed higher activation of MAPK/PI3K signaling pathway and reduction in reactive oxygen species levels compared to CD133 - cells. The in vivo study with a xenograft model showed increased tumor formation in irradiated CD133 + cell-injected nude mice compared to the CD133 - group, suggesting that CD133 contributes to radioresistance in HCC. Therefore, CD133-expressing liver cancer cells have anti-apoptotic and radioresistance properties that may be useful to improve anti-cancer treatments, including chemotherapy/radiotherapy of HCC.

AB - CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure showed higher activation of MAPK/PI3K signaling pathway and reduction in reactive oxygen species levels compared to CD133 - cells. The in vivo study with a xenograft model showed increased tumor formation in irradiated CD133 + cell-injected nude mice compared to the CD133 - group, suggesting that CD133 contributes to radioresistance in HCC. Therefore, CD133-expressing liver cancer cells have anti-apoptotic and radioresistance properties that may be useful to improve anti-cancer treatments, including chemotherapy/radiotherapy of HCC.

KW - CD133

KW - Cancer stem cell

KW - Hepatocellular carcinoma

KW - Microarray

KW - Radioresistance

UR - https://www.scopus.com/pages/publications/84355162060

U2 - 10.1016/j.canlet.2011.10.012

DO - 10.1016/j.canlet.2011.10.012

M3 - Article

C2 - 22079466

AN - SCOPUS:84355162060

SN - 0304-3835

VL - 315

SP - 129

EP - 137

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -